Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review.
Biologics
Guselkumab
IL-23 p19 inhibitors
Psoriasis
Risankizumab
Safety
Tildrakizumab
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
07
04
2023
accepted:
25
05
2023
medline:
11
7
2023
pubmed:
18
6
2023
entrez:
18
6
2023
Statut:
ppublish
Résumé
The approved biologics targeting interleukin (IL)-23 p19 for the treatment of moderate-to-severe plaque psoriasis, including guselkumab, tildrakizumab, and risankizumab, have generally favorable safety profiles. The aim of the current review is to describe in detail the safety of these selective inhibitors. A literature search was performed using PubMed from inception to 1 November 2022, to identify clinical trials and real-world evidence publications using the keywords "guselkumab," "tildrakizumab," and "risankizumab." Overall, the most common adverse events (AEs) associated with IL-23 p19 inhibitors in clinical trials were nasopharyngitis, headache, and upper respiratory tract infections. Rates of serious AEs and AEs of interest, including serious infections, nonmelanoma skin cancer (NMSC), malignancies excluding NMSC, major adverse cardiovascular events, and serious hypersensitivity reactions, were not increased with long-term use in clinical trials. Selectively targeting IL-23 p19 was also not associated with elevated risk of opportunistic infections, tuberculosis reactivation, oral candidiasis, or inflammatory bowel disease. Results from real-world studies were similar, supporting the safe long-term use of these biologics in a wider population of patients with psoriasis, including older patients, patients for whom multiple biologics failed, and those with comorbidities such as obesity, metabolic syndrome, cardiovascular disease, dyslipidemia, diabetes, hypertension, and psoriatic arthritis. This review is limited by the lack of direct comparisons among therapeutic agents due to differences among study designs and safety data reporting methods. In conclusion, the favorable safety profiles of IL-23 p19 inhibitors support their long-term use in the management of patients with moderate-to-severe psoriasis.
Identifiants
pubmed: 37330926
doi: 10.1007/s12325-023-02568-0
pii: 10.1007/s12325-023-02568-0
pmc: PMC10329957
doi:
Substances chimiques
Interleukin-23
0
Interleukin-23 Subunit p19
0
Biological Products
0
Types de publication
Journal Article
Review
Langues
eng
Pagination
3410-3433Informations de copyright
© 2023. The Author(s).
Références
Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157(8):940–6.
pubmed: 34190957
doi: 10.1001/jamadermatol.2021.2007
Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377–90.
pubmed: 28212759
pmcid: 5731650
doi: 10.1016/j.jaad.2016.07.064
Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. Lancet. 2021;397(10281):1301–15.
pubmed: 33812489
doi: 10.1016/S0140-6736(20)32549-6
Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–60.
pubmed: 32427307
doi: 10.1001/jama.2020.4006
Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386(9997):983–94.
pubmed: 26025581
doi: 10.1016/S0140-6736(14)61909-7
Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020;82(1):117–22.
pubmed: 31425723
doi: 10.1016/j.jaad.2019.08.026
Schon MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352(18):1899–912.
pubmed: 15872205
doi: 10.1056/NEJMra041320
Boehncke WH, Brembilla NC. Pathogenesis-oriented therapy of psoriasis using biologics. Expert Opin Biol Ther. 2022;22(12):1463–73.
pubmed: 35815360
doi: 10.1080/14712598.2022.2100219
Puig L. The role of IL 23 in the treatment of psoriasis. Expert Rev Clin Immunol. 2017;13(6):525–34.
pubmed: 28165883
doi: 10.1080/1744666X.2017.1292137
Janssen Biotech. STELARA (ustekinumab) [package insert]. Horsham: Janssen Biotech. 2022. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf . Accessed June 2023.
Megna M, Potestio L, Fabbrocini G, Camela E. Treating psoriasis in the elderly: biologics and small molecules. Expert Opin Biol Ther. 2022;22(12):1503–20.
pubmed: 35695241
doi: 10.1080/14712598.2022.2089020
AbbVie. HUMIRA (adalimumab) [package insert]. 2021. North Chicago: AbbVie. https://www.rxabbvie.com/pdf/humira.pdf . Accessed June 2023.
UCB. CIMZIA (certolizumab pegol) [package insert]. 2019. Georgia: UCB. https://www.cimzia.com/themes/custom/cimzia/docs/CIMZIA_full_prescribing_information.pdf . Accessed June 2023.
Janssen Biotech. REMICADE (infliximab) [package insert]. 2021. Horsham: Janssen Biotech. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/REMICADE-pi.pdf . Accessed June 2023.
Amgen. ENBREL (etanercept) [package insert]. 2022. Thousand Oaks: Amgen. https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Enbrel/enbrel_pi.pdf . Accessed June 2023.
Bausch Health. SILIQ (brodalumab) [package insert]. 2020. Bridgewater: Bristol-Myers Squibb. https://pi.bauschhealth.com/globalassets/BHC/PI/Siliq-pi.pdf . Accessed June 2023.
Eli Lilly. TALTZ (ixekizumab) [package insert]. 2022. Indianapolis: Eli Lilly. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125521s000lbl.pdf . Accessed June 2023.
Novartis. COSENTYX (secukinumab) [package insert]. 2021 East Hanover: Novartis. https://www.novartis.com/us-en/sites/novartis_us/files/cosentyx.pdf . Accessed June 2023.
De Simone C, Amerio P, Amoruso G, et al. Immunogenicity of anti-TNFalpha therapy in psoriasis: a clinical issue? Expert Opin Biol Ther. 2013;13(12):1673–82.
pubmed: 24107126
doi: 10.1517/14712598.2013.848194
Kamata M, Tada Y. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int J Mol Sci. 2020;21(5):1690.
pubmed: 32121574
pmcid: 7084606
doi: 10.3390/ijms21051690
Janssen Biotech. TREMFYA (guselkumab) [package insert]. 2020. Horsham: Janssen Biotech. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf . Accessed June 2023.
AbbVie. SKYRIZI (risankizumab-rzaa) [package insert]. 2022. North Chicago: AbbVie. https://www.rxabbvie.com/pdf/skyrizi_pi.pdf . Accessed June 2023.
Sun Pharma Global. ILUMYA® (tildrakizumab-asmn) [package insert]. 2020. Sharjah: Sun Pharma Global. https://www.ilumya.com/pdfs/Sun_Pharma_ILUMYA_US_Prescribing_Information.pdf . Accessed June 2023.
Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–17.
pubmed: 28057360
doi: 10.1016/j.jaad.2016.11.041
Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–31.
pubmed: 28057361
doi: 10.1016/j.jaad.2016.11.042
Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178(1):114–23.
pubmed: 28635018
doi: 10.1111/bjd.15750
Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831–9.
pubmed: 31402114
doi: 10.1016/S0140-6736(19)31773-8
Reich K, Papp KA, Armstrong AW, et al. Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol. 2019;180(5):1039–49.
pubmed: 30485400
doi: 10.1111/bjd.17454
Reich K, Griffiths CEM, Gordon KB, et al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2020;82(4):936–45.
pubmed: 31809827
doi: 10.1016/j.jaad.2019.11.040
Blauvelt A, Tsai TF, Langley RG, et al. Consistent safety profile with up to 5 years of continuous treatment with guselkumab: pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. J Am Acad Dermatol. 2022;86(4):827–34.
pubmed: 34798201
doi: 10.1016/j.jaad.2021.11.004
Blauvelt A, Lebwohl M, Langley RG, et al. Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2023;S0190–9622(23):00524–8.
Puig L, Tsai TF, Bhutani T, et al. Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials. J Eur Acad Dermatol Venereol. 2020;34(8):1744–9.
pubmed: 32289190
doi: 10.1111/jdv.16460
Foley P, Reich K, Blauvelt A, et al. Serious gastrointestinal-related adverse events among psoriasis patients treated with guselkumab in VOYAGE 1 and VOYAGE 2. J Drugs Dermatol. 2021;20(8):855–60.
pubmed: 34397205
doi: 10.36849/JDD.6216
Reich K, Song M, Li S, et al. Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2. J Dermatol. 2019;46(12):1141–52.
pubmed: 31631377
doi: 10.1111/1346-8138.15109
Youn SW, Yu DY, Kim TY, et al. Efficacy and safety of guselkumab compared with placebo and adalimumab in Korean patients with moderate-to-severe psoriasis: Post-hoc analysis from the phase III, double-blind, placebo- and active-comparator–controlled VOYAGE 1/2 trials. J Dermatolog Treat. 2022;33(1):535–41.
pubmed: 32419536
doi: 10.1080/09546634.2020.1770174
Terui T, Kobayashi S, Okubo Y, et al. Efficacy and safety of guselkumab in Japanese patients with palmoplantar pustulosis: a phase 3 randomized clinical trial. JAMA Dermatol. 2019;155(10):1153–61.
pubmed: 31268476
pmcid: 6613288
doi: 10.1001/jamadermatol.2019.1394
Blauvelt A, Thaçi D, Papp KA, et al. Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials. Br J Dermatol. 2023. https://doi.org/10.1093/bjd/ljad081 .
doi: 10.1093/bjd/ljad081
pubmed: 36994947
Megna M, Potestio L, Ruggiero A, Camela E, Fabbrocini G. Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study. J Dermatolog Treat. 2022;33(5):2560–4.
pubmed: 35098859
doi: 10.1080/09546634.2022.2036674
Ruggiero A, Fabbrocini G, Cinelli E, Megna M. Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti-interleukin-17 treatment: a real-life 52-week retrospective study. Dermatol Ther. 2021;34(1): e14673.
pubmed: 33314658
doi: 10.1111/dth.14673
Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Armario-Hita JC, Pérez-Gil A, Galán-Gutiérrez M. Guselkumab: mid-term effectiveness, drug survival, and safety in real clinical practice. Dermatol Ther. 2021;34(2): e14798.
pubmed: 33484067
doi: 10.1111/dth.14798
Rodriguez-Fernandez-Freire L, Galán-Gutiérrez M, Armario-Hita JC, Pérez-Gil A, Ruiz-Villaverde R. Guselkumab: short-term effectiveness and safety in real clinical practice. Dermatol Ther. 2020;33(3): e13344.
pubmed: 32227659
doi: 10.1111/dth.13344
Snast I, Sherman S, Holzman R, Hodak E, Pavlovsky L. Real-life experience of guselkumab in patients with psoriasis. Dermatol Ther. 2020;33(6): e13964.
pubmed: 32618384
doi: 10.1111/dth.13964
Ruggiero A, Fabbrocini G, Cinelli E, Ocampo Garza SS, Camela E, Megna M. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice. Clin Exp Dermatol. 2022;47(3):561–7.
pubmed: 34642965
doi: 10.1111/ced.14979
Galluzzo M, Talamonti M, Bernardini N, et al. Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year. Expert Opin Biol Ther. 2022;22(12):1585–92.
pubmed: 35708257
doi: 10.1080/14712598.2022.2090835
Gerdes S, Asadullah K, Hoffmann M, et al. Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab. J Eur Acad Dermatol Venereol. 2022;36(9):1568–77.
pubmed: 35569014
doi: 10.1111/jdv.18218
Gerdes S, Bräu B, Hoffmann M, et al. Real-world effectiveness of guselkumab in patients with psoriasis: health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial. J Dermatol. 2021;48(12):1854–62.
pubmed: 34510527
doi: 10.1111/1346-8138.16128
Marletta D, Murgia G, Cattaneo A, Carrera C, Marzano A. Single-centre real-life experience of guselkumab in patients with moderate-to-severe plaque psoriasis. J Drugs Dermatol. 2022;21(8):864–6.
pubmed: 35946964
doi: 10.36849/JDD.6962
Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatolog Treat. 2022;33(6):2813–20.
pubmed: 35603992
doi: 10.1080/09546634.2022.2081655
Michelucci A, Manzo Margiotta F, Panduri S, et al. A real-life experience as a proof of guselkumab effectiveness and safety in patients with moderate to severe psoriasis. Dermatol Ther. 2022;35(4): e15339.
pubmed: 35088508
doi: 10.1111/dth.15339
Medina-Catalán D, Riera P, Pagès-Puigdemont N, et al. A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence. Int J Clin Pharm. 2022;44(3):725–30.
pubmed: 35380392
doi: 10.1007/s11096-022-01400-z
Megna M, Potestio L, Fabbrocini G, Ruggiero A. Long-term efficacy and safety of guselkumab for moderate to severe psoriasis: a 3-year real-life retrospective study. Psoriasis (Auckl). 2022;12:205–12.
pubmed: 35859710
Megna M, Fabbrocini G, Cinelli E, Camela E, Ruggiero A. Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience. J Dermatolog Treat. 2022;33(2):1074–8.
pubmed: 32705907
doi: 10.1080/09546634.2020.1800577
Malara G, Trifirò C, Bartolotta A, et al. Real-world effectiveness and safety of guselkumab for the treatment of psoriasis: a 6-month prospective study in a series of psoriatic patients. Eur Rev Med Pharmacol Sci. 2021;25(1):406–12.
pubmed: 33506930
Maliyar K, O’Toole A, Gooderham MJ. Long-term single center experience in treating plaque psoriasis with guselkumab. J Cutan Med Surg. 2020;24(6):588–95.
pubmed: 32510235
doi: 10.1177/1203475420932514
Galluzzo M, Tofani L, Lombardo P, et al. Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study. J Clin Med. 2020;9(7):2170.
pubmed: 32659978
pmcid: 7408922
doi: 10.3390/jcm9072170
Galluzzo M, Chiricozzi A, Cinotti E, et al. Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations. Expert Opin Biol Ther. 2022;22(3):367–76.
pubmed: 34607513
doi: 10.1080/14712598.2022.1988566
Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276–88.
pubmed: 28596043
doi: 10.1016/S0140-6736(17)31279-5
Gooderham M, Elewski BE, Pariser DM, et al. Incidence of serious gastrointestinal events among tildrakizumab-treated patients with psoriasis: letter to the editor. J Eur Acad Dermatol Venereol. 2019;33(10):e350–2.
pubmed: 31033068
pmcid: 6850306
doi: 10.1111/jdv.15643
Blauvelt A, Reich K, Papp KA, et al. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. Br J Dermatol. 2018;179(3):615–22.
pubmed: 29742274
doi: 10.1111/bjd.16724
Reich K, Warren RB, Iversen L, et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. Br J Dermatol. 2020;182(3):605–17.
pubmed: 31218661
doi: 10.1111/bjd.18232
Thaçi D, Piaserico S, Warren RB, et al. Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). Br J Dermatol. 2021;185(2):323–34.
pubmed: 33544883
doi: 10.1111/bjd.19866
Thaçi D, Gerdes S, Du Jardin KG, Perrot JL, Puig L. Efficacy of tildrakizumab across different body weights in moderate-to-severe psoriasis over 5 years: pooled analyses from the reSURFACE pivotal studies. Dermatol Ther (Heidelb). 2022;12(10):2325–41.
pubmed: 36098877
doi: 10.1007/s13555-022-00793-z
Fernandez AP, Dauden E, Gerdes S, et al. Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2. J Eur Acad Dermatol Venereol. 2022;36(10):1774–83.
pubmed: 35460287
pmcid: 9545614
doi: 10.1111/jdv.18167
Thaçi D, Jullien D, Egeberg A, et al. Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials. J Eur Acad Dermatol Venereol. 2021;35(11):e709–11.
pubmed: 34058035
doi: 10.1111/jdv.17427
Bissonnette R, Fernández-Peñas P, Puig L, Mendelsohn AM, Rozzo SJ, Menter A. Incidence of cardiovascular events among tildrakizumab-treated patients with moderate-to-severe plaque psoriasis: pooled data from three large randomised clinical trials. J Eur Acad Dermatol Venereol. 2020;34(1):e21–4.
pubmed: 31403725
doi: 10.1111/jdv.15866
Menter MA, Mehta NN, Lebwohl MG, et al. The effect of tildrakizumab on cardiometabolic risk factors in psoriasis by metabolic syndrome status: post hoc analysis of two phase 3 trials (ReSURFACE 1 and ReSURFACE 2). J Drugs Dermatol. 2020;19(8):703–8.
pubmed: 32845115
doi: 10.36849/JDD.2020.5337
Augustin M, Thaçi D, Pinter A, Reich K, Lambert J, van de Kerkhof P. Long-term efficacy and safety of tildrakizumab: 5-year results from the reSURFACE 1 and 2 phase III trials in patients with moderate-to-severe plaque psoriasis. EMJ Dermatol. 2021;9:2–11.
Imafuku S, Nakagawa H, Igarashi A, et al. Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: results from a 5-year extension of a phase 3 study (reSURFACE 1). J Dermatol. 2021;48(6):844–52.
pubmed: 33523513
pmcid: 8248015
doi: 10.1111/1346-8138.15763
Tsianakas A, Schwichtenberg U, Pierchalla P, Hinz T, Diemert S, Korge B. Real-world effectiveness and safety of tildrakizumab in long-term treatment of plaque psoriasis: results from the non-interventional, prospective, multicentre study TILOT. J Eur Acad Dermatol Venereol. 2022;37(1):85–92.
pubmed: 36066998
pmcid: 10087575
doi: 10.1111/jdv.18572
Narcisi A, Valenti M, Gargiulo L, et al. Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: a 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis). J Eur Acad Dermatol Venereol. 2022;37(1):93–103.
pubmed: 36156312
pmcid: 10092064
doi: 10.1111/jdv.18594
Drerup KA, Seemann C, Gerdes S, Mrowietz U. Effective and safe treatment of psoriatic disease with the anti-IL-23p19 biologic tildrakizumab: results of a real-world prospective cohort study in nonselected patients. Dermatology. 2022;238(4):615–9.
pubmed: 34775387
doi: 10.1159/000519924
Becher G, Conner S, Ingram JA, et al. A retrospective real-world study of the effectiveness and tolerability of tildrakizumab in UK adults with moderate-to-severe chronic plaque psoriasis. Dermatol Ther (Heidelb). 2022;12(10):2343–54.
pubmed: 36076145
doi: 10.1007/s13555-022-00800-3
Caldarola G, Galluzzo M, Bernardini N, et al. Tildrakizumab in moderate-to-severe plaque psoriasis: a multicenter, retrospective, real-life study. Dermatol Ther. 2022;35(6):e15488.
pubmed: 35384168
pmcid: 9287013
Burlando M, Castelli R, Cozzani E, Parodi A. Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting. Drugs Context. 2021;10:1–4.
Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–61.
pubmed: 30097359
doi: 10.1016/S0140-6736(18)31713-6
Reich K, Gooderham M, Thaçi D, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394(10198):576–86.
pubmed: 31280967
doi: 10.1016/S0140-6736(19)30952-3
Blauvelt A, Leonardi CL, Gooderham M, et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(6):649–58.
pubmed: 32267471
doi: 10.1001/jamadermatol.2020.0723
Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021;184(1):50–9.
pubmed: 32594522
doi: 10.1111/bjd.19341
Ohtsuki M, Fujita H, Watanabe M, et al. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: results from the SustaIMM phase 2/3 trial. J Dermatol. 2019;46(8):686–94.
pubmed: 31237727
pmcid: 6771602
doi: 10.1111/1346-8138.14941
Papp KA, Lebwohl MG, Puig L, et al. Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up. Br J Dermatol. 2021;185(6):1135–45.
pubmed: 34157132
pmcid: 9290992
doi: 10.1111/bjd.20595
Gkalpakiotis S, Cetkovska P, Arenberger P, et al. Risankizumab for the treatment of moderate-to-severe psoriasis: real-life multicenter experience from the Czech Republic. Dermatol Ther (Heidelb). 2021;11(4):1345–55.
pubmed: 34089479
doi: 10.1007/s13555-021-00556-2
Gargiulo L, Ibba L, Pavia G, et al. Real-life effectiveness and safety of risankizumab in 131 patients affected by moderate-to-severe plaque psoriasis: a 52-week retrospective study. Dermatol Ther (Heidelb). 2022;12(10):2309–24.
pubmed: 36063283
doi: 10.1007/s13555-022-00795-x
Caldarola G, Zangrilli A, Bernardini N, et al. Risankizumab for the treatment of moderate-to-severe psoriasis: a multicenter, retrospective, 1 year real-life study. Dermatol Ther. 2022;35(6):e15489.
pubmed: 35385202
pmcid: 9287038
Megna M, Potestio L, Ruggiero A, Camela E, Fabbrocini G. Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study. Dermatol Ther. 2022;35(7):e15524.
pubmed: 35439341
pmcid: 9539505
doi: 10.1111/dth.15524
Borroni RG, Malagoli P, Gargiulo L, et al. Real-life effectiveness and safety of risankizumab in moderate-to-severe plaque psoriasis: a 40-week multicentric retrospective study. Acta Derm Venereol. 2021;101(11):adv00605.
pubmed: 34596230
doi: 10.2340/actadv.v101.283
Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27–40.
pubmed: 30017705
doi: 10.1016/j.jaad.2018.06.057
Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80(1):43–53.
pubmed: 30017706
doi: 10.1016/j.jaad.2018.06.056
Crowley JJ, Warren RB, Cather JC. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2019;33(9):1676–84.
pubmed: 31054215
pmcid: 6771721
doi: 10.1111/jdv.15653
Mastorino L, Dapavo P, Trunfio M, et al. Risk of reactivation of latent tuberculosis in psoriasis patients on biologic therapies: a retrospective cohort from a tertiary care centre in northern Italy. Acta Derm Venereol. 2022;102:adv00821.
pubmed: 36065745
doi: 10.2340/actadv.v102.1982
Ruggiero A, Martora F, Picone V, et al. The impact of COVID-19 infection on patients with psoriasis treated with biologics: an Italian experience. Clin Exp Dermatol. 2022;47(12):2280–2.
pubmed: 35867020
doi: 10.1111/ced.15336
Kašnar AM, Jurić K, Franić A, Čeović R. Current knowledge on psoriasis during the Covid-19 pandemic. Acta Dermatovenerol Croat. 2022;30(2):99–105.
pubmed: 36254542
Camela E, Potestio L, Fabbrocini G, Ruggiero A, Megna M. New frontiers in personalized medicine in psoriasis. Expert Opin Biol Ther. 2022;22(12):1431–3.
pubmed: 35968665
doi: 10.1080/14712598.2022.2113872